CONGRESS GUIDE

ERS International Congress 2016
DETAILED PROGRAMME
MONDAY 05 SEPTEMBER, 2016
PA2392
Effect of dexamethasone on nocturnal breathing in lowlanders with COPD travelling to 3200m
Michael Furian (Zurich, Switzerland), Michael Furian, Mona Lichtblau, Sayaka S. Aeschbacher, Maya Bisang, Alexey
Nikiforov, Tsogyal D. Latshang, Silvia Ulrich, Almaz Aldashev, Talant Sooronbaev, Konrad E. Bloch
PA2393
LATE-BREAKING ABSTRACT: 2-years follow-up (FU) results of ORCADES study: Long-term mandibular
repositioning device (MRD) therapy in patients treated for obstructive sleep apnea (OSA)
Laurent Morin (Saint Priest Cedex, France), Valérie Attali, Jean-Marc Collet, Marie-Pia d’Ortho, Frédéric Goutorbe, Jean-
Baptiste Kerbrat, Hauria Khemliche, Damien Leger, Lionel Lerousseau, Francis Martin, Christelle Monaca, Pierre-Jean
Monteyrol, Laurent Morin, Eric Mullens, Bernard Pigearias, Jean-Claude Meurice, Marie-Françoise Vecchierini
T-15 Session 388 12:50 - 14:40
Thematic Poster: Pulmonary hypertension: the clinic II
Chairs : Horst Olschewski (GRAZ, Austria), Frederic Perros (Le Plessis-Robinson, France), Robin Condliffe (Sheffield, United
Kingdom), John Wort (Hampton, United Kingdom)
PA2394
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire:
Results from the SYMPHONY study with macitentan
Kelly Chin (Dallas, United States of America), Kelly Chin, Richard Channick, Aryeh Fischer, Robert Frantz, Mardi
Gomberg-Maitland, Leah Kleinman, Chad Miller, Elke Hunsche, Rohan Zamanian, David Badesch
PA2395
PA2396
PA2397
PA2398
PA2399
PA2400
PA2401
PA2402
PA2403
PA2404
PA2405
PA2406
Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
Gabor Kovacs (Graz, Austria), Gabor Kovacs, Alexander Avian, Philipp Douschan, Vasile Foris, Andrea Olschewski, Horst
Olschewski
Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial
hypertension
Benjamin Egenlauf (Heidelberg, Germany), Benjamin Egenlauf, Johanna Ohnesorge, Nicola Benjamin, Christine Fischer,
Yeliz Enderle, Jürgen Burhenne, Andrea Huppertz, Alexandra Carls, Walter-Emil Haefeli, Ekkehard Grünig
Pharmacokinetic interactions in different combinations of pulmonary arterial hypertension treatment
Benjamin Egenlauf (Heidelberg, Germany), Benjamin Egenlauf, Johanna Ohnesorge, Satenik Harutyunova, Nicola
Benjamin, Christine Fischer, Yeliz Enderle, Jürgen Burhenne, Christian Nagel, Andrea Huppertz, Alexandra Carls, Walter-
Emil Haefeli, Ekkehard Grünig
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution
Carlos Fernandez (Bridgewater, United States of America), David Han, Carlos Fernandez, Eugene Sullivan, Danlin Xu,
Walter Perkins, Mona Darwish, Chris Rubino
Response to treatment assessment in patients with PAH by MRI based computational modelling
Angela Lungu (Sheffield, United Kingdom), Angela Lungu, Rod Hose, David Capener, David Kiely, Jim Wild, Andrew
Swift
Physical activity (PA) in pulmonary arterial hypertension (PAH) can be predicted by questionnaire
Benjamin Garfield (London, United Kingdom), Benjamin Garfield, Dongmin Shao, Richard Paul, Lisa Parfitt, Carl Harries,
Laura Price, Paul Kemp, Michael Polkey, John Wort
Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT
Marc Humbert (Le Kremlin-Bicêtre, France), Marc Humbert (Paris, France), Marc Humbert, Hossein-Ardeschir Ghofrani,
Dennis Busse, Janethe de Olivereira Pena, David Langleben
An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK
pulmonary rehabilitation (PR) programme
Laura Moth (London, United Kingdom), Laura Moth, Lauren Hogg, Lynn McDonnell, Meera Patel, Philip Marino
Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009)
Carlos Fernandez (Bridgewater, United States of America), David Han, Carlos Fernandez, Eugene Sullivan, Danlin Xu,
Walter Perkins, Mona Darwish, Chris Rubino
Improving identification and early referral of pulmonary hypertension patients
Lola Loewenthal (London, United Kingdom), Lola Loewenthal, Emily Shaw, Brendan Madden
Prognostic impact of oxygen saturation during the 6-minute walk test in pulmonary arterial hypertension
Mario Santos (Porto, Portugal), Mario Santos, Ines Furtado, Fabienne Goncalves, Luisa Carvalho, Abilio Reis
Treatment of pulmonary arterial hypertension in elderly and very elderly patients
Marylise Ginoux (Bron, France), Marylise Ginoux, Ségolène Turquier, Julie Traclet, Chahera Khouatra, Francois Philit,
Agathe Senechal, Jean-Charles Glerant, Jean-Francois Mornex, Jean-Francois Cordier, Vincent Cottin
165 26.08.2016